The University of Delaware is making major strides in the biopharma sector by launching the new SABRE Center. Backed by $45 million in federal funding, including $10 million from the American Rescue Plan, this 90,000-square-foot hub is set to propel the university into a leader in biopharmaceutical innovation and production. It is situated at UD’s STAR campus, a nexus for cutting-edge technology and research. The SABRE Center isn’t just about research—it’s also gearing up to house a pilot-scale biomanufacturing facility and run an extensive training program to equip the next generation of biopharma experts. This investment underlines the federal government’s commitment to supporting initiatives that blend education, research, and practical applications to secure the nation’s health future and economic prosperity.
Strategic Growth and Workforce Development
The SABRE Center at the University of Delaware (UD) is igniting excitement among state leaders, including UD President Dennis Assanis and NIIMBL Director Kelvin Lee, both avid supporters of its potential to spur biopharmaceutical breakthroughs and workforce development. The facility is attracting industry interest with its cutting-edge testing capabilities aligned with FDA standards. Senators Chris Coons and Tom Carper are vocal proponents, with Coons citing the center’s impact on Delaware’s economic future and Carper focusing on its educational role for upcoming biopharma professionals.
Located near the Ammon Pinizzotto Biopharmaceutical Innovation Center, the SABRE Center promises a collaborative environment conducive to revolutionary work in biopharma, reflecting the university’s growing stature and signaling Delaware’s ascent as a life sciences nexus.
